Lead Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

Age

65 - 75 years

Sex

ALL

Healthy Volunteers

No

•Patients aged 65-75
•Patients with de novo or secondary acute myeloid leukemia (AML) - intermediate or high risk according to European LeukemiaNet (ELN) recommendations 2017
•Untreated patients at diagnosis of acute myeloid leukemia - patients may have received treatment for high-risk myelodysplastic syndromes with hypomethylating agents (HMA). They should not have received a course of induction chemotherapy to be eligible for this study
•Haploidentical family stem cell donor or other suitable donors available
•Fit and unfit patients by geriatric scale assessment
•Signed informed consent.

•Acute Myeloid Leukemia good risk according to European LeukemiaNet 2017
•Positive serology for Human Immunodeficiency Virus.
•Serious organ dysfunction: left ventricular ejection fraction \< 40%, forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) \<50% of predicted, Liver Function Tests \> 5 x the upper limit of normal, or creatinine clearance \<30 ml/min .
•Life expectancy less than 30 days.
•Frail patients by geriatric scale assessment

Related studies

NCT05133882 · Acute Myeloid Leukemia, Adult

NCT06199557 · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult

NCT04050280 · Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, and more

NCT05703126 · Acute Myeloid Leukemia, Adult, Cardiotoxicity, and more

NCT05001828 · Acute Myeloid Leukemia, Adult

Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75